Remiges Ventures, a US-based cross-border venture capital firm with offices in Seattle, WA and Tokyo, Japan, closed its second fund, Remiges BioPharma Fund II, at $95m.
LPs include new and returning investors, such as Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan), 1Globe Capital, LLC (Boston, MA), EA Pharma Co., Ltd. (Tokyo, Japan) and Senju Pharmaceutical Co., Ltd. (Osaka, Japan).
Led by Taro Inaba, Founder and Managing Partner, the firm also launched RDiscovery, a new life sciences incubator to nurture and advance early-stage therapeutic concepts and technologies. RDiscovery will operate as a wholly owned subsidiary of Remiges Ventures, allowing for an efficient transition of projects from pre-seed, early development to a stage where company formation and investment syndication makes sense.
RDiscovery will serve as an integrated innovation engine extending the capacity and capabilities of Remiges Ventures to execute on its strategy of harnessing novel science from Japanese academia and launching it on a patient-centered and commercially-focused path.